DBV Technologies Aligns Viaskin Peanut Patch with FDA Guidance

The biopharmaceutical firm confirmed that recent dialogues with federal regulators have shaped the final preparation of its Biologics License Application. According to the company, the FDA provided specific input on the development process but stopped short of requesting additional clinical trials or supplementary data. This development marks a significant step forward for the patch, which functions by delivering microgram doses of peanut protein through the skin to desensitize the immune system.

By moving into the final phase of regulatory preparation, DBV Technologies aims to bring its non-invasive immunotherapy to a demographic with few current medical alternatives. The company's timeline for a third-quarter submission reflects the progress made during these recent collaborative sessions, ensuring the application meets the agency’s technical requirements before formal review.